DOI: 10.1111/j.1540-8183.2002.tb01045.x. Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction

Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction

10.1111/j.1540-8183.2002.tb01045.x

Crossref journal-article

Wiley

Journal of Interventional Cardiology (311)

Abstract

Fibrinolytic therapy for the treatment of ST‐segment elevation myocardial infarction unquestionably reduces mortality when administered within 12 hours of symptom onset. By promptly restoring antegrade perfusion, infarct size is limited, ventricular function is less compromised, and mortality rates are lowered. Although fibrinolytic therapy initially restores antegrade flow in the infarct vessel in the majority of patients, sustained, tissue‐level reperfusion occurs in only approximately one fourth of patients. Thrombin and platelets associated with a coronary thrombus are not specifically targeted by fibrinolytic agents, but rather have paradoxically increased activity. These components contribute to the tendency for vessel reocclusion after initially successful reperfusion. Thus, adjunctive therapy with antithrombins and antiplatelet agents are essential in the successful treatment of a coronary thrombus. Although aspirin has been shown to reduce mortality in acute myocardial infarction, it is a weak antiplatelet agent that is pathway specific. Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents that block the final common pathway for platelet aggregation. Thus, the growing evidence of platelet preeminence in the pathophysiology of failed thrombolysis has lead to the study of combination drug therapy with glycoprotein IIb/IIIa inhibition and reduced dose fibrinolytic agents in the treatment of acute ST‐segment elevation myocardial infarction. This article reviews the rationale, results, and clinical implications of the major trials of combination drug therapy in acute myocardial infarction.

Bibliography

VIVEKANANTHAN, D. P., PATEL, V. B., & MOLITERNO, D. J. (2002). Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction. Journal of Interventional Cardiology, 15(2), 131â139. Portico.

Authors 3

DEEPAK P. VIVEKANANTHAN (first)
VASANT B. PATEL (additional)
DAVID J. MOLITERNO (additional)

References 58 Referenced 4

{'key': 'e_1_2_1_2_2', 'first-page': '397', 'article-title': "Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)", 'volume': '1', 'author': 'The GISSI Investigators.', 'year': '1986', 'journal-title': 'Lancet'} / Lancet / Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) by The GISSI Investigators. (1986)
{'key': 'e_1_2_1_3_2', 'first-page': '349', 'article-title': 'Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group', 'volume': '2', 'author': 'The ISIS Investigators.', 'year': '1988', 'journal-title': 'Lancet'} / Lancet / Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group by The ISIS Investigators. (1988)
10.1056/NEJM199309023291001
{'key': 'e_1_2_1_5_2', 'first-page': '545', 'article-title': 'Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo‐controlled clinical trial. AIMS Trial Study Group', 'volume': '1', 'author': 'The AIMS Trial Study Group.', 'year': '1988', 'journal-title': 'Lancet'} / Lancet / Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo‐controlled clinical trial. AIMS Trial Study Group by The AIMS Trial Study Group. (1988)
10.1001/jama.1993.03510100061033
10.1016/S0140-6736(94)91161-4
10.1056/NEJM198710013171402
10.1161/01.CIR.85.6.2090
10.1016/S0735-1097(86)80329-1
10.1016/0735-1097(92)90265-O
10.1016/0735-1097(92)90131-6
10.1016/0735-1097(89)90399-9
10.1016/S0140-6736(96)07120-6
10.1161/01.CIR.99.15.1972
10.1016/S0002-9149(99)00736-5
10.1016/0735-1097(95)00372-X
10.1161/01.CIR.82.3.781
10.1161/01.CIR.88.3.1361
10.2165/00003495-199244030-00002
10.1056/NEJM199710163371603
10.1016/S0140-6736(99)07403-6
10.1161/01.CIR.94.5.911
10.1016/0002-9149(90)90525-6
10.1136/hrt.67.2.122
10.1016/0735-1097(94)00360-3
10.1161/01.CIR.97.2.211
10.1161/01.CIR.77.3.678
10.1161/01.CIR.77.3.670
10.1159/000138817
10.1161/01.CIR.81.2.617
10.1172/JCI113446
10.1161/01.CIR.83.3.1038
10.1016/0735-1097(90)90364-U
10.1161/01.CIR.89.4.1802
10.1161/01.CIR.82.1.169
10.1097/00005344-199601000-00017
10.1161/01.ATV.13.5.738
10.1016/0735-1097(93)90041-X
10.1161/01.CIR.95.4.846
10.1016/S0735-1097(98)00474-4
10.1161/01.CIR.99.21.2720
10.1161/01.CIR.101.3.239
{'key': 'e_1_2_1_44_2', 'first-page': '1', 'article-title': 'Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes', 'volume': '2', 'author': 'Cannon CP', 'year': '1998', 'journal-title': 'Cardiology Rounds'} / Cardiology Rounds / Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes by Cannon CP (1998)
10.1161/01.CIR.101.24.2788
10.1016/S0735-1097(01)01758-2
10.1016/S0140-6736(00)05059-5
10.1016/S0140-6736(01)05775-0
10.1161/01.CIR.103.21.2550
10.1056/NEJMoa010746
10.1001/jama.282.4.341
10.1016/S0735-1097(98)00579-8
10.1001/jama.284.12.1549
10.1056/NEJM200106213442503
10.1056/NEJM198709033171001
10.1056/NEJM200106213442501
10.1067/mhj.2001.113574
10.1016/S0735-1097(00)00923-2
{'key': 'e_1_2_1_59_2', 'first-page': '8B', 'article-title': 'Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: New therapeutic regimen for acute myocardial infarction', 'volume': '12', 'author': 'Patel VB', 'year': '2000', 'journal-title': 'J Invasive Cardiol'} / J Invasive Cardiol / Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: New therapeutic regimen for acute myocardial infarction by Patel VB (2000)

Dates

Type	When
Created	18 years, 2 months ago (July 2, 2007, 5:35 a.m.)
Deposited	1 year, 9 months ago (Nov. 18, 2023, 8:25 a.m.)
Indexed	1 year, 9 months ago (Nov. 18, 2023, 7:06 p.m.)
Issued	23 years, 5 months ago (April 1, 2002)
Published	23 years, 5 months ago (April 1, 2002)
Published Online	18 years, 2 months ago (July 2, 2007)
Published Print	23 years, 5 months ago (April 1, 2002)

Funders 0

None

BibTeX

@article{VIVEKANANTHAN_2002, title={Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction}, volume={15}, ISSN={1540-8183}, url={http://dx.doi.org/10.1111/j.1540-8183.2002.tb01045.x}, DOI={10.1111/j.1540-8183.2002.tb01045.x}, number={2}, journal={Journal of Interventional Cardiology}, publisher={Wiley}, author={VIVEKANANTHAN, DEEPAK P. and PATEL, VASANT B. and MOLITERNO, DAVID J.}, year={2002}, month=apr, pages={131–139} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2023,
        11,
        19
      ]
    ],
    "date-time": "2023-11-19T00:06:54Z",
    "timestamp": 1700352414137
  },
  "reference-count": 58,
  "publisher": "Wiley",
  "issue": "2",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2007,
            7,
            2
          ]
        ],
        "date-time": "2007-07-02T00:00:00Z",
        "timestamp": 1183334400000
      },
      "content-version": "vor",
      "delay-in-days": 1918,
      "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2002,
        4
      ]
    ]
  },
  "abstract": "<jats:p>Fibrinolytic therapy for the treatment of ST\u2010segment elevation myocardial infarction unquestionably reduces mortality when administered within 12 hours of symptom onset. By promptly restoring antegrade perfusion, infarct size is limited, ventricular function is less compromised, and mortality rates are lowered. Although fibrinolytic therapy initially restores antegrade flow in the infarct vessel in the majority of patients, sustained, tissue\u2010level reperfusion occurs in only approximately one fourth of patients. Thrombin and platelets associated with a coronary thrombus are not specifically targeted by fibrinolytic agents, but rather have paradoxically increased activity. These components contribute to the tendency for vessel reocclusion after initially successful reperfusion. Thus, adjunctive therapy with antithrombins and antiplatelet agents are essential in the successful treatment of a coronary thrombus. Although aspirin has been shown to reduce mortality in acute myocardial infarction, it is a weak antiplatelet agent that is pathway specific. Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents that block the final common pathway for platelet aggregation. Thus, the growing evidence of platelet preeminence in the pathophysiology of failed thrombolysis has lead to the study of combination drug therapy with glycoprotein IIb/IIIa inhibition and reduced dose fibrinolytic agents in the treatment of acute ST\u2010segment elevation myocardial infarction. This article reviews the rationale, results, and clinical implications of the major trials of combination drug therapy in acute myocardial infarction.</jats:p>",
  "DOI": "10.1111/j.1540-8183.2002.tb01045.x",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2007,
        7,
        2
      ]
    ],
    "date-time": "2007-07-02T09:35:41Z",
    "timestamp": 1183368941000
  },
  "page": "131-139",
  "source": "Crossref",
  "is-referenced-by-count": 4,
  "title": "Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction",
  "prefix": "10.1111",
  "volume": "15",
  "author": [
    {
      "given": "DEEPAK P.",
      "family": "VIVEKANANTHAN",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "VASANT B.",
      "family": "PATEL",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "DAVID J.",
      "family": "MOLITERNO",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "311",
  "published-online": {
    "date-parts": [
      [
        2007,
        7,
        2
      ]
    ]
  },
  "reference": [
    {
      "key": "e_1_2_1_2_2",
      "first-page": "397",
      "article-title": "Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)",
      "volume": "1",
      "author": "The GISSI Investigators.",
      "year": "1986",
      "journal-title": "Lancet"
    },
    {
      "key": "e_1_2_1_3_2",
      "first-page": "349",
      "article-title": "Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102. ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group",
      "volume": "2",
      "author": "The ISIS Investigators.",
      "year": "1988",
      "journal-title": "Lancet"
    },
    {
      "key": "e_1_2_1_4_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM199309023291001"
    },
    {
      "key": "e_1_2_1_5_2",
      "first-page": "545",
      "article-title": "Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo\u2010controlled clinical trial. AIMS Trial Study Group",
      "volume": "1",
      "author": "The AIMS Trial Study Group.",
      "year": "1988",
      "journal-title": "Lancet"
    },
    {
      "key": "e_1_2_1_6_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/jama.1993.03510100061033"
    },
    {
      "key": "e_1_2_1_7_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0140-6736(94)91161-4"
    },
    {
      "key": "e_1_2_1_8_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM198710013171402"
    },
    {
      "key": "e_1_2_1_9_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.85.6.2090"
    },
    {
      "key": "e_1_2_1_10_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0735-1097(86)80329-1"
    },
    {
      "key": "e_1_2_1_11_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(92)90265-O"
    },
    {
      "key": "e_1_2_1_12_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(92)90131-6"
    },
    {
      "key": "e_1_2_1_13_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(89)90399-9"
    },
    {
      "key": "e_1_2_1_14_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0140-6736(96)07120-6"
    },
    {
      "key": "e_1_2_1_15_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.99.15.1972"
    },
    {
      "key": "e_1_2_1_16_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0002-9149(99)00736-5"
    },
    {
      "key": "e_1_2_1_17_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(95)00372-X"
    },
    {
      "key": "e_1_2_1_18_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.82.3.781"
    },
    {
      "key": "e_1_2_1_19_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.88.3.1361"
    },
    {
      "key": "e_1_2_1_20_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.2165/00003495-199244030-00002"
    },
    {
      "key": "e_1_2_1_21_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM199710163371603"
    },
    {
      "key": "e_1_2_1_22_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0140-6736(99)07403-6"
    },
    {
      "key": "e_1_2_1_23_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.94.5.911"
    },
    {
      "key": "e_1_2_1_24_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0002-9149(90)90525-6"
    },
    {
      "key": "e_1_2_1_25_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1136/hrt.67.2.122"
    },
    {
      "key": "e_1_2_1_26_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(94)00360-3"
    },
    {
      "key": "e_1_2_1_27_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.97.2.211"
    },
    {
      "key": "e_1_2_1_28_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.77.3.678"
    },
    {
      "key": "e_1_2_1_29_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.77.3.670"
    },
    {
      "key": "e_1_2_1_30_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1159/000138817"
    },
    {
      "key": "e_1_2_1_31_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.81.2.617"
    },
    {
      "key": "e_1_2_1_32_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1172/JCI113446"
    },
    {
      "key": "e_1_2_1_33_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.83.3.1038"
    },
    {
      "key": "e_1_2_1_34_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(90)90364-U"
    },
    {
      "key": "e_1_2_1_35_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.89.4.1802"
    },
    {
      "key": "e_1_2_1_36_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.82.1.169"
    },
    {
      "key": "e_1_2_1_37_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1097/00005344-199601000-00017"
    },
    {
      "key": "e_1_2_1_38_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.ATV.13.5.738"
    },
    {
      "key": "e_1_2_1_39_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0735-1097(93)90041-X"
    },
    {
      "key": "e_1_2_1_40_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.95.4.846"
    },
    {
      "key": "e_1_2_1_41_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0735-1097(98)00474-4"
    },
    {
      "key": "e_1_2_1_42_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.99.21.2720"
    },
    {
      "key": "e_1_2_1_43_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.101.3.239"
    },
    {
      "key": "e_1_2_1_44_2",
      "first-page": "1",
      "article-title": "Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes",
      "volume": "2",
      "author": "Cannon CP",
      "year": "1998",
      "journal-title": "Cardiology Rounds"
    },
    {
      "key": "e_1_2_1_45_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.101.24.2788"
    },
    {
      "key": "e_1_2_1_46_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0735-1097(01)01758-2"
    },
    {
      "key": "e_1_2_1_47_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0140-6736(00)05059-5"
    },
    {
      "key": "e_1_2_1_48_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0140-6736(01)05775-0"
    },
    {
      "key": "e_1_2_1_49_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1161/01.CIR.103.21.2550"
    },
    {
      "key": "e_1_2_1_50_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJMoa010746"
    },
    {
      "key": "e_1_2_1_51_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/jama.282.4.341"
    },
    {
      "key": "e_1_2_1_52_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0735-1097(98)00579-8"
    },
    {
      "key": "e_1_2_1_53_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/jama.284.12.1549"
    },
    {
      "key": "e_1_2_1_54_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM200106213442503"
    },
    {
      "key": "e_1_2_1_55_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM198709033171001"
    },
    {
      "key": "e_1_2_1_56_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM200106213442501"
    },
    {
      "key": "e_1_2_1_57_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1067/mhj.2001.113574"
    },
    {
      "key": "e_1_2_1_58_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0735-1097(00)00923-2"
    },
    {
      "key": "e_1_2_1_59_2",
      "first-page": "8B",
      "article-title": "Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: New therapeutic regimen for acute myocardial infarction",
      "volume": "12",
      "author": "Patel VB",
      "year": "2000",
      "journal-title": "J Invasive Cardiol"
    }
  ],
  "container-title": "Journal of Interventional Cardiology",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1540-8183.2002.tb01045.x",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1540-8183.2002.tb01045.x",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2023,
        11,
        18
      ]
    ],
    "date-time": "2023-11-18T13:25:26Z",
    "timestamp": 1700313926000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://onlinelibrary.wiley.com/doi/10.1111/j.1540-8183.2002.tb01045.x"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2002,
        4
      ]
    ]
  },
  "references-count": 58,
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2002,
          4
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1111/j.1540-8183.2002.tb01045.x"
  ],
  "URL": "http://dx.doi.org/10.1111/j.1540-8183.2002.tb01045.x",
  "relation": {},
  "ISSN": [
    "0896-4327",
    "1540-8183"
  ],
  "subject": [],
  "container-title-short": "J Interven Cardiology",
  "published": {
    "date-parts": [
      [
        2002,
        4
      ]
    ]
  }
}